Research programme: wound healing therapy - TA Therapeutics

Drug Profile

Research programme: wound healing therapy - TA Therapeutics

Alternative Names: Wound healing therapy research programme - TA Therapeutics

Latest Information Update: 12 Mar 2010

Price : $50

At a glance

  • Originator Geron Corporation; TA Therapeutics
  • Class Gene therapies; Small molecules
  • Mechanism of Action Telomerase activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Wounds

Most Recent Events

  • 12 Mar 2010 Preclinical development is ongoing in USA
  • 29 Jul 2003 This programme is still in active development
  • 19 Jun 2001 Preclinical development for Wounds in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top